6 pharma stocks that made news this week

Dicerna Pharmaceuticals
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Inc. (DRNA) has returned more than 55% in the last 5 trading days.

The Company is involved in developing subcutaneously delivered ribonucleic acid interference (RNAi)-based pharmaceuticals to treat chronic liver diseases, cardiovascular diseases and viral infectious diseases.

Recent events:

-- On October 16, 2017, the Company filed a clinical trial application (CTA) for DCR-PHXC for primary hyperoxaluria to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
--On November 2, 2017, the Company entered into an agreement with Boehringer Ingelheim to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis.

As per the deal terms, Boehringer Ingelheim will pay Dicerna up to $201 million in upfront and success-based development and commercialization milestones, excluding royalties, for an undisclosed target.

Near-term catalysts:

-- Upon approval by the MHRA in the United Kingdom, a phase I study of DCR-PHXC for primary hyperoxaluria is expected to be conducted in the first quarter of 2018.
-- File an IND application in the U.S. and/or CTA in Europe for a second candidate for an undisclosed rare disease involving the liver in the second quarter of 2018.
-- File an IND application in the U.S. or CTA in Europe for DCR-HBVS program, which targets HBV directly, at approximately the end of 2018.

DRNA closed Thursday’s (Nov.9th) trading at $8.02, up 0.12%.